Stock Market Strategy: The Launch of A New Quantitative Fund Compass Rose-RCM

January 14th, 2015

Jan.1 2015 Marks the Rise of our Quant Fund, Compass Rose-RCM, using our Proprietary QSEP Algorithm Our QSEP platform (Quantitative Systematic Execution Protocol) represents the culmination of 2 years worth of  tireless research, late night coding sessions and the synthesis of a combined 75+ years of investing experience. The result, a system designed to outperform annual [...]

Credit to Equity: Credit Struggling to confirming Equity Rally This Morning

January 13th, 2015

Courtesy of MJ the Credit Guru at MS Howells The strength of this morning’s equity market open was never truly reflected in the US credit markets. We have argued that the recent equity market highs have not been corroborated with anything close to an equally bullish credit market. This makes us hesitant to believe that [...]

Precious Metals Outlook: Fortune’s Favor Precious Metals Partnership up 9.25% First Three Days of January 2015

January 7th, 2015

The FFPM Partnership has gained 9.25%(unaudited) in the first three days of the New Year, offsetting the decline of 2014. Our primary concentration in the shares of high grade North American intermediate gold producers is responsible for this out performance verses the gain of 3.1% for gold during this period.  We are hopeful higher gold [...]

Credit To Equity: Credit Cautious as Equities Outperform‏

December 15th, 2014

Courtesy of MJ Credit Guru MS Howells Broad Market US and European Corporate credit market Indices are opening slightly stronger, however, many of the corporate credit market’s worst performing companies and sectors are continuing to widen. For example, RIG is opening 21bps wider at ~721bps while WFT, NBR, and TCK are opening 3-7bps wider. US [...]

News and Notes: Biotechs to Keep on the Radar Immunogen & Kite Pharma

December 15th, 2014

IMGN Immunogen disclosed Eli Lilly exercised its rights under its Multi-Target Agreement with ImmunoGen t (10.01 ) On December 11, 2014, Eli Lilly exercised its rights under its Multi-Target Agreement with ImmunoGen to take two licenses for exclusive rights to develop and commercialize anticancer products to two undisclosed targets using our antibody-drug conjugate technology. Lilly [...]

Credit to Equity Update: Divergence not this Severe Since 2007

December 11th, 2014

Recent equity market rally at odds with corporate credit market’s caution (Courtesy of Mike Johnson of MS Howell) Today, the CDX High Yield index is slightly lower and the IG index has surrendered nearly all its gains while the S&P 500 is up nearly 24pts. In our opinion, this divergence between the corporate credit and [...]

Stock Market Strategy: The Definitive Work on Intel (INTC)

December 5th, 2014

Courtesy of Russ Fischer SeekingAlpha Intel And Inevitability Summary Inevitability leads to predictability and gains in the stock market. The explosive growth of solid state drives in inevitable. Intel has a breakthrough cost on the raw material for solid state drives. The best investments I have ever made – investments that have made up 90%+ [...]

Rosenthal Research Focus: Non Volatile Random Access Memory (NVRAM) The Resurgence of Intel (INTC)

November 17th, 2014

Intel: More Good News About The Mobile Losses (Courtesy of Russ Fischer) Summary The losses on the mobile division are truly enormous. If the losses are R&D costs, what are they R&Ding? If they are primarily development costs, they can decrease rather quickly. Last week I wrote a piece on the Intel (NASDAQ:INTC) mobile losses. Basically it [...]

Stock Market Strategy: Why Stock Markets are Selling Off in Dramatic Fashion in One Easy Chart

October 15th, 2014

Courtesy of The Chart below does not require much of an introduction. Suffice it to say:  QE3 Ends + Record Amounts of Margin Debt = Vicious Stock Market Sell Off.  We have seen this process unfold before. At the end of QE1 in 2010 and QE2 in 2011 the S&P500 dropped about 20% from [...]


October 14th, 2014

Courtesy of Prohost Biotech – Monday, October 13, 2014 A lot of talk, writings and insinuations were, and still are filling the media prior to, and following the FDA granting Gilead (GILD) approval for its all-oral HCV combination pill Harvoni. All that has been mentioned to date is questionable, except the fact that people infected with genotype 1a and [...]